New Developments in Lymphoma Spring 2014 Newsletter

Message from John Leonard, MD Program Director

Leonard Face

“It is my pleasure as director of the WCMC Lymphoma Program to introduce the inaugural issue of our newsletter. We designed this letter to be informative to both patients and clinicians.”

Click here for the full article.

 Lymphoma Program Highlights

We believe that the future of oncology lies in targeted, non-chemotherapy drugs. Over the past year,  research at WCMC contributed to the FDA approval of ibrutinib, four papers in the New England Journal  of Medicine, and multiple presentations at the annual meetings of the American Society of Hematology and the International Conference on Malignant Lymphoma. The following are short summaries of some of our success stories.


Oral Therapy Improves Survival in Chronic Lymphocytic Leukemia
Dr. Richard Furman


Chemotherapy-Free Combination is Active as First-Line Treatment of Mantle Cell Lymphoma
Dr. Jia Ruan


Idelalisib is active in patients with Chemotherapy and Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
Dr. Peter Martin

Clinical Trial Spotlight

This is a select list of our open trials. Currently there are over 30 open trials for various lymphomas at WCMC.  A complete listing of our offerings can be found at:

 Patient Experience

A current WCMC patient writes about his experience in seeking treatment with the Lymphoma Program at WCMC.

“In January 2012, I began experiencing a sore right knee, and swollen glands in my neck and left side. Lacking a fever, I went to see my local physician, who agreed I had a palpable mass in my neck, and I was referred to an otolaryngologist for a biopsy. This procedure revealed a preliminary diagnosis of non-Hodgkin lymphoma…” Click here for the full article.

Post a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: